


PHARMACEUTICAL 2022

SYNLOGIC INC. Rank 223 of 475







PHARMACEUTICAL 2022

SYNLOGIC INC. Rank 223 of 475



The relative strengths and weaknesses of SYNLOGIC INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of SYNLOGIC INC. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 65% points. The greatest weakness of SYNLOGIC INC. is the variable Research and Development, reducing the Economic Capital Ratio by 79% points.

The company's Economic Capital Ratio, given in the ranking table, is -83%, being 193% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	133,309
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	10,080
Liabilities, Non-Current	17,390
Other Assets	32,339
Other Compr. Net Income	-59
Other Expenses	0
Other Liabilities	0
Other Net Income	204
Property and Equipment	9,088
Research and Development	47,127
Revenues	1,754
Selling, General and Administrative Expense	15,392

Output Variable	Value in 1000 USD
Assets	174,736
Liabilities	27,470
Expenses	62,519
Stockholders Equity	147,266
Net Income	-60,561
Comprehensive Net Income	-60,590
Economic Capital Ratio	-83%